<DOC>
	<DOCNO>NCT02355535</DOCNO>
	<brief_summary>This Phase I dose escalation study evaluate Procaspase Activating Compound-1 ( PAC-1 ) , small molecule activates procaspase -3 caspase-3 , result apoptosis cancer cell , patient advance malignancy . PAC-1 take orally day 1-21 28-day cycle . The maximum tolerated dose ( MTD ) PAC-1 ( 5 dose level ) determine use modified-Fibonacci dose-escalation 3+3 design . Treatment continue disease progression , unacceptable toxicity , physician discretion , patient refusal .</brief_summary>
	<brief_title>Procaspase Activating Compound-1 ( PAC-1 ) Treatment Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<criteria>1 . Male female ≥ 18 year age 2 . Diagnosis advance solid tumor hematologic malignancy ( limited lymphoma ) fail become intolerant standard therapy 3 . Has measurable disease , define least 1 tumor fulfills criteria target lesion accord RECIST 1.1 , lymphoma fulfills Deauville PET Criteria 4 . Has ECOG PS 0 , 1 , 2 5 . Has total bilirubin &lt; 1.5 mg/dL , serum albumin &gt; 3.0 gm/dL , AST ALT &lt; 1.5 ULN &lt; 3 x ULN subject know hepatic metastasis 6 . Has serum creatinine &lt; 1.5 × ULN 7 . Has hemoglobin ≥ 10 g/dL , ANC ≥ 1.5 × 109/L , platelet count ≥ 100 × 109/L 8 . Must able take oral medication maintain fast require 2 hour 1 hour capsule ( ) administration 9 . Must willing able comply study 10 . Has read , understood , sign ICF 11 . Women childbearing potential must pregnant breastfeeding . In addition , medically acceptable method birth control must use total abstinence . Women postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) consider WOCP 12 . Men surgically medically sterile must agree use acceptable method contraception . Male patient female sexual partner pregnant , possibly pregnant , could become pregnant study must agree use condom least one month last dose study drug . Total abstinence study period acceptable alternative 13 . Prior systemic treatment metastatic disease permit may ongoing , include targeted therapy , biologic response modifier , chemotherapy , hormonal therapy , investigational therapy 14 . Willingness donate blood biomarker study relate type therapy use trial tumor type treat 1 . Had surgery within 4 week prior study treatment except minor procedure ( hepatic biliary stent placement allow ) 2 . Gliomas exclude , well history brain metastasis , seizure underlie brain injury 3 . May receive cytotoxic chemotherapy , targeted therapy , biologic response modifier , chemotherapy , hormonal therapy within last 3 week , nitrosureas within last 6 week prior study treatment . 4 . Has history blood clot , pulmonary embolism , DVT unless control anticoagulant treatment 5 . Has history arterial thromboembolic event within prior six month include CVA , TIA , MI , unstable angina 6 . Has uncontrolled HIV hepatitis B C 7 . Has clinically significant infection 8 . Has severe , uncontrolled medical condition , include uncontrolled DM unstable CHF 9 . Radiation therapy 25 % bone marrow 10 . Prior allogeneic bone marrow organ transplantation 11 . &gt; Grade 1 peripheral neuropathy within 14 day enrollment . 12 . Patient receive investigational drug 14 day enrollment 13 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation 14 . Abnormalities 12lead electrocardiogram ( ECG ) consider investigator clinically significant ( acute ischemia , leave bundle branch block , ventricular arrhythmia ) baseline prolongation ratecorrected QT interval ( e.g. , repeated demonstration QTc interval &gt; 480 millisecond ) 15 . Presence nonhealing wound , fracture , ulcer 16 . Has condition , opinion investigator , might jeopardize safety patient interfere protocol compliance 17 . Has mental medical condition prevents patient give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>refractory</keyword>
	<keyword>intolerant</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
</DOC>